Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.cmi.2021.11.010
Title: | Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study | Authors: | Chia, PY Ong, SWX Chiew, CJ Ang, LW Chavatte, JM Mak, TM Cui, L Kalimuddin, S Chia, WN Tan, CW Chai, LYA Tan, SY Zheng, S Lin, RTP Wang, L Leo, YS Lee, VJ Lye, DC Young, BE |
Keywords: | Breakthrough infection COVID-19 Delta SARS-CoV-2 Vaccination Vaccine breakthrough Variants of concern COVID-19 COVID-19 Vaccines Cohort Studies Humans Kinetics Pandemics Retrospective Studies SARS-CoV-2 Vaccination Vaccines, Synthetic mRNA Vaccines |
Issue Date: | 1-Apr-2022 | Publisher: | Elsevier BV | Citation: | Chia, PY, Ong, SWX, Chiew, CJ, Ang, LW, Chavatte, JM, Mak, TM, Cui, L, Kalimuddin, S, Chia, WN, Tan, CW, Chai, LYA, Tan, SY, Zheng, S, Lin, RTP, Wang, L, Leo, YS, Lee, VJ, Lye, DC, Young, BE (2022-04-01). Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Clinical Microbiology and Infection 28 (4) : 612.e1-612.e7. ScholarBank@NUS Repository. https://doi.org/10.1016/j.cmi.2021.11.010 | Abstract: | Objectives: Highly effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed but variants of concerns are worrisome, especially B.1.617.2 (Delta) which has rapidly spread across the world. We aim to study if vaccination alters virological and serological kinetics in breakthrough infections. Methods: We conducted a multicentre retrospective cohort study of patients in Singapore who had received a licensed mRNA vaccine and been admitted to hospital with B.1.617.2 SARS-CoV-2 infection. We compared clinical features, virological and serological kinetics (anti-nucleocapsid, anti-spike and surrogate virus neutralization titres) between fully vaccinated and unvaccinated individuals. Results: Out of 218 individuals with B.1.617.2 infection, 84 received an mRNA vaccine of which 71 were fully vaccinated, 130 were unvaccinated and four received a non-mRNA vaccine. Despite significantly older age in the vaccine breakthrough group, only 2.8% (2/71) developed severe COVID-19 requiring oxygen supplementation compared with 53.1% (69/130) in the unvaccinated group (p < 0.001). Odds of severe COVID-19 following vaccination were significantly lower (adjusted odds ratio 0.07 95% CI 0.015–0.335, p 0.001). PCR cycle threshold values were similar between vaccinated and unvaccinated groups at diagnosis, but viral loads decreased faster in vaccinated individuals. Early, robust boosting of anti-spike protein antibodies was observed in vaccinated patients; however, these titres were significantly lower against B.1.617.2 than the wildtype vaccine strain. Discussion: The mRNA vaccines are highly effective at preventing symptomatic and severe COVID-19 associated with B.1.617.2 infection. Vaccination is associated with faster decline in viral RNA load and a robust serological response. Vaccination remains a key strategy for control of the COVID-19 pandemic. | Source Title: | Clinical Microbiology and Infection | URI: | https://scholarbank.nus.edu.sg/handle/10635/228436 | ISSN: | 1198743X 14690691 |
DOI: | 10.1016/j.cmi.2021.11.010 |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections a multicentre cohort study.pdf | Published version | 1.21 MB | Adobe PDF | CLOSED | None |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.